Cited by 257CAR-T cell therapy researchMultiple Myeloma Research and TreatmentsImmunotherapy and Immune Responses

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Mailankody, Sham, Matous, Jeffrey V., Chhabra, Saurabh, Liedtke, Michaela, Sidana, Surbhi, Oluwole, Olalekan O., Malik, Shahbaz, Nath, Rajneesh, Anwer, Faiz, Cruz, Jose Carlos, Htut, Myo, Karski, Erin E., Lovelace, Wade, Dillon, Myles, Butz, Eric, Ying, Wendy, Balakumaran, Arun, Kumar, Shaji K.·2023·Nature Medicine

DOI 10.1038/s41591-022-02182-7

Open this paper in CoChat — free account

Abstract

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating doses of ALLO-715 after lymphodepletion with an anti-CD52 antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoing first-in-human phase 1 UNIVERSAL trial. Primary objectives included determination of the safety and tolerability of ALLO-715 and the safety profile of the ALLO-647-containing lymphodepletion regimen. Key secondary endpoints were response rate and duration of response. Grade ≥3 adverse events were reported in 38 (88.0%) of patients. Cytokine release syndrome was observed in 24 patients (55.8%), with 1 grade ≥3 event (2.3%) and neurotoxicity in 6 patients (14%), with no grade ≥3 events. Infections occurred in 23 patients (53.5%), with 10 (23.3%) of grade ≥3. Overall, 24 patients (55.8%) had a response. Among patients treated with 320 × 10 6 CAR+ T cells and a fludarabine-, cyclophosphamide- and ALLO-647-based lymphodepletion regimen (n = 24), 17 (70.8%) had a response including 11 (45.8%) with very good partial response or better and 6 (25%) with a complete response/stringent complete response. The median duration of response was 8.3 months. These initial results support the feasibility and safety of allogeneic CAR T cell therapy for myeloma.

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02182-7

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citation
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citation
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,525
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Self-citation
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citation
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M. A., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 667
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citation
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
Novak, A. J., Darce, J. R., Arendt, B. K., Harder, B., Henderson, K., Kindsvogel, W., Gross, J. A., Greipp, P. R., & Jelinek, D. F. (2003) · Blood · doi:10.1182/blood-2003-06-2043 · Cited by 556
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Benjamin, R., Graham, C., Yallop, D., Jozwik, A., Mirci‐Danicar, O., Lucchini, G., Pinner, D., Jain, N., Kantarjian, H., Boissel, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32334-5 · Cited by 387
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Usmani, S. Z., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., Miguel, J. F. S., Oriol, A., Rosiñol, L., Chari, A., Bhutani, M., Karlin, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01338-6 · Cited by 344
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
Sommer, C., Boldajipour, B. A., Kuo, T. C., Bentley, T., Sutton, J. E., Chen, A., Geng, T., Dong, H., Galetto, R., Valton, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.001 · Cited by 156
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A., Callander, N., Sborov, D., Suvannasankha, A., et al. (2021) · Cancer · doi:10.1002/cncr.33809 · Cited by 144
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Harrison, S. J., Minnema, M. C., Lee, H. C., Spencer, A., Kapoor, P., Madduri, D., Larsen, J., Ailawadhi, S., Kaufman, J. L., Raab, M. S., et al. (2020) · Blood · doi:10.1182/blood-2020-134063 · Cited by 112
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
Sommer, C., Cheng, H., Nguyen, D., Dettling, D. E., Yeung, Y. A., Sutton, J. E., Hamze, M., Valton, J., Smith, J. N. P., Djuretic, I. M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.022 · Cited by 104
Bispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 102
Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era
Sassine, J., Khawaja, F., Shigle, T. L., Handy, V., Foolad, F., Aitken, S. L., Jiang, Y., Champlin, R. E., Shpall, E. J., Rezvani, K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab298 · Cited by 89
ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T
Neelapu, S. S., Nath, R., Munoz, J. L., Tees, M. T., Miklos, D. B., Frank, M. J., Malik, S. A., Stevens, D. A., Shin, C. R., Balakumaran, A., et al. (2021) · Blood · doi:10.1182/blood-2021-146038 · Cited by 49
Self-citation
Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
García‐Guerrero, E., Sierro-Martínez, B., & Pérez‐Simón, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01128 · Cited by 48
Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation
Hua, J., Zhang, J., Zhang, X., Wu, X., Zhou, L., Bao, X., Han, Y., Miao, M., Li, C., Fu, C., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01140-6 · Cited by 38
Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design
Nooka, A. K., Weisel, K. C., van de Donk, N. W. C. J., Routledge, D. J. M., Rodríguez‐Otero, P., Song, K., Quach, H., Callander, N. S., Minnema, M. C., Trudel, S., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1269 · Cited by 37
Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
Maybury, B. D., Cook, G., Pratt, G., Yong, K., & Ramasamy, K. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.004 · Cited by 19
P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)
Nastoupil, L. J., O'Brien, S. M., Holmes, H. E., Dsouza, L. A., Hart, D., Matsuda, E., Satterfield-Ledbetter, T., Skoble, J., Garner, E., Bryan, M., et al. (2022) · HemaSphere · doi:10.1097/01.hs9.0000848676.15840.df · Cited by 19
T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma
Mailankody, S., & Landgren, O. (2022) · New England Journal of Medicine · doi:10.1056/nejme2209692 · Cited by 16
Self-citation
Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies
Dhakal, B., Chhabra, S., Savani, B. N., & Hamadani, M. (2021) · British Journal of Haematology · doi:10.1111/bjh.17904 · Cited by 14
Self-citation
Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar TTM Cell Therapy for the Treatment of Multiple Myeloma
Sommer, C., Lin, R., Sutton, J. E., Bentley, T., Nguyen, D., Yoon, H., Au, M., Vargas‐Inchaustegui, D. A., Cheng, H., Blarcom, T. V., et al. (2020) · Blood · doi:10.1182/blood-2020-141477 · Cited by 10
Recent updates on bispecific T-cell engager (BiTE) antibodies in relapsed and refractory multiple myeloma.
Rafae, A., Wahab, A., Ehsan, H., Christy, J. J., Saleem, T., Kandah, E., Ali, R. S., Malik, M. N., Ali, S., Saeed, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.e20034 · Cited by 8
Self-citation

Research works printed but not linked: 1

Prevention and Treatment of Cancer-Related Infections (Version 3.2022). NCCN Clinical Practice Guidelines in Oncology, Vol. 2022 (National Comprehensive Cancer Network, 2022).

Sorted by citations

Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,503
From bench to bedside: the history and progress of CAR T cell therapy
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q. F., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 526
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 443
CAR T Cells and T-Cell Therapies for Cancer
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 412
Current understanding and management of CAR T cell-associated toxicities
Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 352

See all 257

Authors: Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., Htut, M., Karski, E. E., Lovelace, W., Dillon, M., Butz, E., Ying, W., Balakumaran, A., & Kumar, S. K.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Colorado Blood Cancer Institute (US)
Medical College of Wisconsin (US)
Stanford Medicine (US)
Vanderbilt University Medical Center (US)
St David's Medical Center (US)
Banner MD Anderson Cancer Center (US)
Cleveland Clinic (US)
City Of Hope National Medical Center (US)
Allogene Therapeutics (United States) (US)
Mayo Clinic (US)
Corresponding author: Mailankody, Sham
ORCID: Mailankody, Sham
Chhabra, Saurabh
Liedtke, Michaela
Sidana, Surbhi
Oluwole, Olalekan O.
Malik, Shahbaz
Nath, Rajneesh
Anwer, Faiz
Htut, Myo
Ying, Wendy
Kumar, Shaji K.
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2023-01-23
Volume: 29
Issue: 2
Pages: 422-429
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/s41591-022-02182-7
OpenAlex: W4317802192
Cited by: 257
References: 31
Citations by year: 2026: 42 · 2025: 57 · 2024: 96 · 2023: 60
FWCI: 31.02
Type: journal article
Language: en
Update notices: correction (2023-03-17)
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P30CA008748)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: allogeneic CAR T cells, BCMA, multiple myeloma, relapsed/refractory multiple myeloma, anti-CD52 antibody, lymphocyte depletion, graft-versus-host disease prophylaxis, cytokine release syndrome, neurotoxicity, safety and tolerability, response rate, duration of response
MeSH terms: Cyclophosphamide, Humans, Multiple Myeloma, T-Lymphocytes, Immunotherapy, Adoptive, Hematopoietic Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks